Shenzhen Neptunus Bioengineering Co Ltd (000078) - Total Liabilities
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has total liabilities worth CN¥23.58 Billion CNY (≈ $3.45 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Neptunus Bioengineering Co Ltd - Total Liabilities Trend (1995–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Shenzhen Neptunus Bioengineering Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
China | CN¥11.86 Billion |
|
Legacy Housing Corp
NASDAQ:LEGH
|
USA | $52.48 Million |
|
Fireweed Zinc Ltd
V:FWZ
|
Canada | CA$15.54 Million |
|
Rio2 Ltd
V:RIO
|
Canada | CA$87.09 Million |
|
Standard Chartered PLC
LSE:STAN
|
UK | GBX643.99 Billion |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
China | CN¥1.94 Billion |
|
Tilray Inc
NASDAQ:TLRY
|
USA | $549.12 Million |
|
ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd
SHG:603976
|
China | CN¥735.16 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Shenzhen Neptunus Bioengineering Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shenzhen Neptunus Bioengineering Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Neptunus Bioengineering Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
The table below shows the annual total liabilities of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥24.16 Billion ≈ $3.53 Billion |
-6.93% |
| 2024-12-31 | CN¥25.95 Billion ≈ $3.80 Billion |
-7.59% |
| 2023-12-31 | CN¥28.09 Billion ≈ $4.11 Billion |
-6.82% |
| 2022-12-31 | CN¥30.14 Billion ≈ $4.41 Billion |
-0.51% |
| 2021-12-31 | CN¥30.30 Billion ≈ $4.43 Billion |
-6.00% |
| 2020-12-31 | CN¥32.23 Billion ≈ $4.72 Billion |
-3.26% |
| 2019-12-31 | CN¥33.32 Billion ≈ $4.88 Billion |
-1.92% |
| 2018-12-31 | CN¥33.97 Billion ≈ $4.97 Billion |
+39.25% |
| 2017-12-31 | CN¥24.39 Billion ≈ $3.57 Billion |
+126.22% |
| 2016-12-31 | CN¥10.78 Billion ≈ $1.58 Billion |
+1.55% |
| 2015-12-31 | CN¥10.62 Billion ≈ $1.55 Billion |
+35.29% |
| 2014-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+28.02% |
| 2013-12-31 | CN¥6.13 Billion ≈ $897.19 Million |
+27.56% |
| 2012-12-31 | CN¥4.81 Billion ≈ $703.35 Million |
+24.38% |
| 2011-12-31 | CN¥3.86 Billion ≈ $565.47 Million |
+19.08% |
| 2010-12-31 | CN¥3.25 Billion ≈ $474.87 Million |
+31.27% |
| 2009-12-31 | CN¥2.47 Billion ≈ $361.76 Million |
+23.81% |
| 2008-12-31 | CN¥2.00 Billion ≈ $292.19 Million |
-9.97% |
| 2007-12-31 | CN¥2.22 Billion ≈ $324.56 Million |
-16.42% |
| 2006-12-31 | CN¥2.65 Billion ≈ $388.31 Million |
-16.58% |
| 2005-12-31 | CN¥3.18 Billion ≈ $465.46 Million |
+39.76% |
| 2004-12-31 | CN¥2.28 Billion ≈ $333.03 Million |
-11.99% |
| 2003-12-31 | CN¥2.59 Billion ≈ $378.42 Million |
+89.30% |
| 2002-12-31 | CN¥1.37 Billion ≈ $199.91 Million |
+27.81% |
| 2001-12-31 | CN¥1.07 Billion ≈ $156.41 Million |
+68.71% |
| 2000-12-31 | CN¥633.55 Million ≈ $92.71 Million |
+45.11% |
| 1999-12-31 | CN¥436.59 Million ≈ $63.89 Million |
+725.49% |
| 1998-12-31 | CN¥52.89 Million ≈ $7.74 Million |
-39.90% |
| 1997-12-31 | CN¥88.00 Million ≈ $12.88 Million |
+31.62% |
| 1996-12-31 | CN¥66.86 Million ≈ $9.78 Million |
+120.11% |
| 1995-12-31 | CN¥30.37 Million ≈ $4.44 Million |
-- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more